Login to Your Account



Financings NEWS
HONG KONG – Opening the door wide to a broad range of investments, a European biotech investment firm is working with a diversified Chinese biotech company to invest in and introduce mature and innovative technologies to Greater China.

As an advisory panel for the FDA prepared to take up the matter Tuesday of safety issues with Astrazeneca plc’s marketed dipeptidyl peptidase-4 inhibitor for diabetes, Viking Therapeutics Inc. lowered the target for its IPO in a move that could help the firm advance the licensing deal with Ligand Pharmaceuticals Inc. 

Shanghai-based Ark Biosciences Inc. has received financial backing, the amount undisclosed, to usher its lead candidate through phase II trials in Australia and possibly other sites. 

More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: